10-Q: Orchestra BioMed Holdings Reports Q1 2025 Results, Faces Going Concern Uncertainty

Orchestra BioMed Holdings reports increased revenue but a larger net loss in Q1 2025, while also expressing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Summary

• Orchestra BioMed Holdings reported a net loss of $18.755 million for the three months ended March 31, 2025, compared to a net loss of $13.463 million for the same period in 2024.
• Total revenue increased to $868,000 from $620,000 year-over-year, driven by growth in both partnership and product revenue.
• Research and development expenses rose to $13.482 million, up from $9.112 million in the prior year, due to increased spending on the BACKBEAT study and Virtue SAB program.
• The company has substantial doubt about its ability to continue as a going concern, as its cash, cash equivalents, and short-term investments may not be sufficient to fund operations for the next twelve months.
• Orchestra BioMed is exploring options to raise additional capital through equity or debt issuances, partnerships, and other financing structures.
• The company received FDA Breakthrough Device Designation for its AVIM therapy and FDA approval for an IDE amendment to initiate an updated design of its planned clinical trial for its Virtue SAB product candidate.
• The company is in a mediation procedure with Terumo for mutually agreeable adjustments to the Terumo Agreement with the purpose of restructuring milestone payments as well as making other potential material modifications to that agreement, including additional financial commitments by Terumo to the Company and the Virtue SAB program.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the widening net loss and going concern uncertainty weigh heavily on the outlook. The FDA designations are positive, but the financial challenges are significant.

Positives

• Total revenue increased by 40% to $868,000, with partnership revenue rising to $732,000 and product revenue reaching $136,000.
• The company received FDA Breakthrough Device Designation for its AVIM therapy and FDA approval for an IDE amendment to initiate an updated design of its planned clinical trial for its Virtue SAB product candidate.

Negatives

• Orchestra BioMed's Q1 2025 net loss widened to $18.755 million from $13.463 million in Q1 2024.
• The company expresses substantial doubt about its ability to continue as a going concern due to insufficient capital to fund operations for the next 12 months.

Risks

• The company's cash, cash equivalents, and short-term investments may not be sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Delays in the Virtue SAB program due to COVID-19, supply chain issues, and regulatory changes may impact the company's ability to meet milestones under the Terumo Agreement.
• The company is in a mediation procedure with Terumo for mutually agreeable adjustments to the Terumo Agreement with the purpose of restructuring milestone payments as well as making other potential material modifications to that agreement, including additional financial commitments by Terumo to the Company and the Virtue SAB program.
• The company must maintain Qualified Cash (as defined in the 2024 LSA) in an amount greater than or equal to (x) the outstanding principal amount of the Term Loan advances, multiplied by (y) (1) prior to December 1, 2025, 35% or (2) on and after December 1, 2025, (A) if the Performance Milestone Date (as defined in the 2024 LSA) has not occurred on or prior to December 1, 2025, 50% until the date on which the Performance Milestone Date has occurred and (B) on and after the Performance Milestone Date, 35% (the Minimum Cash Covenant).
• The company's future viability is dependent on its ability to raise additional capital to finance its operations.

Future Outlook

The company expects operating expenses to increase to support clinical study costs and additional research and development expenses. The amount and timing of future funding requirements are dependent on many factors, including the cost and pace of execution of clinical studies and research and development activities, the strength of results from clinical studies and other research, development and manufacturing efforts, as well as the potential receipt of revenues or other payments or investments under a restructured Terumo Agreement, the Medtronic Agreement and/or future collaborations, and the realization of cash from the acquisition of Vivasure by Haemonetics.

Industry Context

Orchestra BioMed operates in the highly competitive biomedical device industry, facing competition from larger companies. The company's success depends on clinical trial outcomes, regulatory approvals, and market acceptance of its product candidates.

Comparison to Industry Standards

• The company's Virtue Trial will compare Virtue SAB to Boston Scientific Corporation's AGENT drug coated balloon (DCB), currently the only DCB FDA-approved for a coronary indication.
• The company has an exclusive license and collaboration agreement with Medtronic, Inc. for the development and commercialization of AVIM therapy for the treatment of HTN in patients indicated for a cardiac pacemaker.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees may be affected by potential cost-cutting measures.
• Customers and partners may experience uncertainty due to the company's financial situation.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company plans to initiate enrollment of the Virtue Trial during the second half of 2025.
• The company is in a mediation procedure with Terumo for mutually agreeable adjustments to the Terumo Agreement with the purpose of restructuring milestone payments as well as making other potential material modifications to that agreement, including additional financial commitments by Terumo to the Company and the Virtue SAB program.
• The company will continue to prioritize its spending on its AVIM therapy program and the execution of its BACKBEAT study.

Key Dates

Keywords

Orchestra BioMed, AVIM therapy, Virtue SAB, Medtronic, Terumo, Financial Results, Going Concern, Clinical Trials, FDA, Revenue, Net Loss, R&D Expenses, Capital Raise